Order Article Reprints

Romaniello D, Marrocco I, Belugali Nataraj N, Ferrer I, Drago-Garcia D, Vaknin I, Oren R, Lindzen M, Ghosh S, Kreitman M, et al. Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. Cancers. 2020; 12(9):2394. https://doi.org/10.3390/cancers12092394

Romaniello, Donatella, Ilaria Marrocco, Nishanth Belugali Nataraj, Irene Ferrer, Diana Drago-Garcia, Itay Vaknin, Roni Oren, Moshit Lindzen, Soma Ghosh, Matthew Kreitman, and et al. 2020. "Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor" Cancers 12, no. 9: 2394. https://doi.org/10.3390/cancers12092394

Romaniello, D., Marrocco, I., Belugali Nataraj, N., Ferrer, I., Drago-Garcia, D., Vaknin, I., Oren, R., Lindzen, M., Ghosh, S., Kreitman, M., Kittel, J. C., Gaborit, N., Bergado Baez, G., Sanchez, B., Eilam, R., Pikarsky, E., Paz-Ares, L., & Yarden, Y. (2020). Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. Cancers, 12(9), 2394. https://doi.org/10.3390/cancers12092394